SCHEMBL7762813

SCHEMBL7762813

CCCCCCCCCCCCSCC(NC(=O)c1cccc(N(C)C)c1)C(=O)O.O=CCCl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.42
KMT2A Q03164 1/20 0.42
KDM4E B2RXH2 2/20 0.39
LMNA P02545 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CCKBR P32239 2/20 0.38
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37
ALOX15 P16050 1/20 0.37
HSD17B10 Q99714 1/20 0.37
TMEM97 Q5BJF2 1/20 0.37
SIGMAR1 Q99720 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC4 P56524 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC7 Q8WUI4 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC10 Q969S8 1/20 0.37
HDAC11 Q96DB2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7757472 0.87 HDAC3 (0.47) KMT2ALMNASMN1; SMN2ALDH1A1HSD17B10
SCHEMBL7757470 0.78 HDAC3 (0.47) KMT2ALMNASMN1; SMN2ALDH1A1HSD17B10
SCHEMBL7757475 0.78 HDAC3 (0.49) LMNASMN1; SMN2ALDH1A1HSD17B10HDAC3
SCHEMBL4951769 0.75 HDAC3 (0.55) KMT2ALMNASMN1; SMN2ALDH1A1HSD17B10
SCHEMBL7757493 0.73 PPARA (0.53) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL7763910 0.71 CES1 (0.45) POLBMAPTHSD17B10ICMT
SCHEMBL7762826 0.71 GMNN (0.38) POLBMAPTHSD17B10ICMT
SCHEMBL4953001 0.70 HDAC3 (0.51) KMT2ALMNAALDH1A1HSD17B10HDAC3
SCHEMBL12029285 0.67 ITGB3 (0.55) POLBLMNASMN1; SMN2MAPT
SCHEMBL12546589 0.67 BCL2L1 (0.52) KMT2ALMNAALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6251882-B1 TREATING LEUKEMIA, BREAST CANCER, PROSTATE CANCER, OR BRAIN TUMOR PARKER HUGHES INSTITUTE 2001-06-26 US claimed
EP-1091934-A2 ALKYL KETONES AS POTENT ANTI-CANCER AGENTS Parker Hughes Institute (US) 2001-04-18 EP claimed
WO-2000000469-A2 ALKYL KETONES AS POTENT ANTI-CANCER AGENTS PARKER HUGHES INSTITUTE (US) 2000-01-06 WO claimed
US-6251882-B1 TREATING LEUKEMIA, BREAST CANCER, PROSTATE CANCER, OR BRAIN TUMOR PARKER HUGHES INSTITUTE 2001-06-26 US disclosed
EP-1091934-A2 ALKYL KETONES AS POTENT ANTI-CANCER AGENTS Parker Hughes Institute (US) 2001-04-18 EP disclosed
WO-2000000469-A2 ALKYL KETONES AS POTENT ANTI-CANCER AGENTS PARKER HUGHES INSTITUTE (US) 2000-01-06 WO disclosed